RxDoctor Payments Data

Wilburn Bolton, MD

Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1225267289

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Abbott at 36.9% of the total. 2025 is the largest year on record at $17,127, more than ten times the $931 reported in 2019.

$52,293in general payments, 2019–2025

Across 706 payments — averaging $74.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • Lilly USA, LLC$16K
  • Amgen$6K
  • Xeris Pharmaceuticals, Inc.$3K
  • Novo Nordisk$2K
  • Bayer$736
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$8,45916%
  • Speaking & faculty fees$29,04456%
  • Travel & lodging$2,4785%
  • Food & beverage$12,24423%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,293 in reported general payments places this provider in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama

Medicare billing

Part B allowed, 2024
$105,957
Medicare patients
258
Services billed
2,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$274,722
MounjaroTirzepatide178$271,379
JardianceEmpagliflozin108$124,040
Tresiba Flextouch U-100Insulin Degludec82$78,659
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog105$68,984
JanuviaSitagliptin Phosphate67$56,099
FarxigaDapagliflozin Propanediol43$54,771
Xultophy 100-3.6Insulin Degludec/Liraglutide25$45,813
TrulicityDulaglutide28$34,038
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$32,556
Fiasp FlextouchInsulin Aspart (Niacinamide)19$27,404
Tresiba Flextouch U-200Insulin Degludec15$23,434
Nano 2nd Gen Pen NeedlePen Needle, Diabetic78$13,178
Humalog Kwikpen U-100Insulin Lispro38$12,638
NovologInsulin Aspart33$11,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$1,862$332,402226 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$16,419$308,190225 claims
Boehringer IngelheimJardiance$222$124,040108 claims
MerckJanuvia$13$56,09967 claims
AstraZenecaFarxiga$527$54,77143 claims
AbbVieSynthroid$84$6,40672 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$60$2,941310 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

Other endocrinology, diabetes & metabolism in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →